Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism
Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism
复制标题
DOI：
10.1016/j.fertnstert.2005.07.1311
复制
发表时间：
2006-02-01
影响因子：
6.7
通讯作者：
Muderris, II
中科院分区：
文献类型：
--
作者：
Batukan, C;Muderris, II
目的：本研究代表了长期的临床和生化结果，以及不同身体部位对口服炔雌醇/屈螺酮联合药物治疗多毛或无多囊卵巢综合征（PCOS）患者的反应。设计：前瞻性、开放性、对照临床研究。设置：Erciyes大学医学院门诊患者。患者：招募了50名中度至重度多毛症女性。两名妇女失去了随访。干预（S）：妇女与3毫克屈螺酮和30微克炔雌醇治疗12 cycles.Main结果Measure（S）：多毛症进行了评估，在6个月的时间间隔使用Ferriman-Gallwey（F-G）评分系统。治疗6个月和12个月时血清FSH、LH、总睾酮（T）、游离睾酮（T）、雄烯二酮（A）、硫酸脱氢表雄酮（DHEAS）、雌二醇（E-2）和性激素结合球蛋白（SHBG）水平与基线值进行比较。胸部和腹部的改善最明显，其次是上唇和下巴。在背部和手臂上观察到的影响最小。血清总水平和游离T和A下降，而SHBG水平增加显着6个月和12个月后，与基线levels. Conclusions（S）：屈螺酮/炔雌醇组合发挥显着的抗雄激素，活性和有效地改善面部多毛症。六个周期后，有益效果最为明显，此后以较慢的速度持续。
Objective: This study represents long term clinical and biochemical results and the response of different body parts to medical therapy with oral ethinyl estradiol/drospirenone combination in hirsute patients with or without polycystic ovary syndrom (PCOS).Design: Prospective, open, controlled clinical study.Setting: Outpatients at Erciyes University Medical School.Patient(s): Fifty women with moderate to severe hirsutism were recruited. Two women were lost to follow-up.Intervention(s): Women were treated with 3 mg of drospirenone and 30 mu g of ethinyl estradiol for 12 cycles.Main Outcome Measure(s): Hirsutism was assessed at 6-month intervals using the Ferriman-Gallwey (F-G) scoring system. Serum FSH, LH, total and free testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS), estradiol (E-2), and sex-hormone binding globulin (SHBG) levels at 6 and 12 months of therapy were compared with baseline values.Result(s): Total mean FG score declined by 67% and 78% after 6 and 12 months, respectively. Improvement was most prominent on the chest and abdomen, followed by the upper lip and chin. The lowest effect was observed on the back and arms. Serum levels of total and free T and A decreased, whereas SHBG levels increased significantly after 6 and 12 months when compared with baseline levels.Conclusion(s): Drospirenone/ethinyl estradiol combination exerts significant antiandrogenic, activity and is effective in improving facial hirsutism. The beneficial effect is most obvious after six cycles and continues thereafter at a slower rate.